Telehealth Pharmacy Services and ePrescribing

Telehealth pharmacy services connect the clinical encounter — wherever it happens — to the dispensing of medication, and ePrescribing is the electronic infrastructure that makes that connection possible. The pairing matters because most telehealth visits end with a prescription, and whether that prescription gets filled efficiently, legally, and safely depends on a layered set of technical, regulatory, and clinical rules. Telehealth prescribing rules vary significantly by drug class, state, and whether a prior in-person relationship exists — making this one of the more consequential dimensions of virtual care.

Definition and scope

ePrescribing (electronic prescribing) is the transmission of a prescription order from a licensed prescriber to a pharmacy using a certified electronic system, bypassing paper or verbal orders. In a telehealth context, that prescriber may be hundreds of miles from the patient and may have never met them in person. The Drug Enforcement Administration (DEA) and the Centers for Medicare & Medicaid Services (CMS) both regulate pieces of this transaction — the DEA controls what can be prescribed for controlled substances, while CMS shapes ePrescribing standards for Medicare Part D.

The scope of telehealth pharmacy services extends beyond the act of prescribing itself. It includes:

1. Medication therapy management (MTM) conducted via video or phone — pharmacists reviewing a patient's complete drug regimen without a prescribing transaction occurring.
2. ePrescribing for non-controlled medications — the most common type, governed by state pharmacy board rules and transmitted through certified networks like Surescripts.
3. Electronic prescribing for controlled substances (EPCS) — tightly regulated by DEA 21 CFR Part 1311, requiring two-factor authentication and DEA-registered software.
4. Mail-order and specialty pharmacy integration — where a telehealth platform routes a prescription directly to a fulfillment pharmacy, sometimes within the same corporate structure.

Telehealth policy and regulation shapes which of these pathways are open on any given date, and that policy landscape has shifted substantially since 2020.

How it works

A standard ePrescribing workflow in telehealth follows a predictable sequence, though the controls applied at each step differ based on the drug class.

The prescriber completes a clinical evaluation — synchronous video, telephone, or in some cases asynchronous review of patient-submitted data through store-and-forward telehealth. The prescriber then enters the order into a certified EHR or standalone ePrescribing platform. That system applies clinical decision support checks (drug-drug interactions, allergy alerts, dosing flags), then transmits the order to the patient's chosen pharmacy through a real-time network, typically Surescripts, which processes over 20 billion transactions annually according to Surescripts' own published network data.

For controlled substances, an additional authentication layer is required. DEA regulations under 21 CFR Part 1311 mandate identity proofing of the prescriber and two-factor credential verification at the time of signing. The signed order is logged with a digital audit trail. Pharmacies receiving EPCS orders must also use DEA-registered software to accept and verify them.

The prescribing event also intersects with telehealth HIPAA compliance requirements: the transmission must use encrypted channels, the pharmacy system is a covered entity, and business associate agreements govern any intermediary platform handling protected health information.

Common scenarios

The range of medications prescribed via telehealth platforms is broader than many assume. Urgent care telehealth services routinely issue prescriptions for antibiotics, antivirals (including oseltamivir for influenza), and topical treatments. Mental health platforms — which represent a significant share of telehealth volume — frequently prescribe antidepressants, anxiolytics, and, in platforms with psychiatrists on staff, stimulants for ADHD management. Mental health telehealth has its own prescribing considerations, particularly around Schedule II controlled substances like amphetamines.

Dermatology provides a clean illustration of asynchronous ePrescribing: a patient submits photographs through a store-and-forward platform, a dermatologist reviews the images and clinical history offline, and issues a prescription for a topical retinoid or antifungal — no live video required. Telehealth for dermatology relies heavily on this model.

Chronic disease telehealth generates a different pattern: ongoing prescription renewals for maintenance medications — antihypertensives, statins, thyroid drugs — where the telehealth visit functions as a monitoring touchpoint rather than a diagnostic encounter. Remote vital signs data from remote patient monitoring devices can inform these prescribing decisions in real time.

Decision boundaries

The central question in telehealth ePrescribing is not whether it can be done, but what constraints apply. Those constraints fall into two distinct categories.

Regulatory constraints are the hard boundaries. The DEA's Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person medical evaluation before a controlled substance can be prescribed via telemedicine. During the COVID-19 public health emergency, DEA issued blanket exceptions under 21 CFR Part 1306 allowing Schedule III–V controlled substances to be prescribed via telehealth without prior in-person visits — exceptions that have since moved toward a more permanent rule structure under DEA's proposed special registration framework, though finalization remains ongoing as of the DEA's 2023 rulemaking dockets.

Telehealth state laws and licensure add a second layer: 50 separate state pharmacy practice acts, each defining what constitutes a valid prescriber-patient relationship. A prescriber licensed only in Texas cannot legally issue prescriptions for a patient physically located in California, regardless of the technical capability of the platform.

Clinical constraints are the softer but equally real boundaries. Prescribing without a physical examination carries inherent diagnostic risk. The absence of a stethoscope or blood pressure cuff is not a bureaucratic technicality — it means certain medication decisions carry higher uncertainty. Telehealth platforms have responded by integrating peripheral device data from wearable health devices and telehealth tools, but the evidentiary gap between a home blood pressure reading and a clinical measurement is real and recognized in prescribing guidelines from organizations including the American Heart Association.

The comparison that clarifies most of the confusion: ePrescribing for a non-controlled medication after a synchronous video visit for a urinary tract infection is essentially equivalent, legally and clinically, to an in-person visit and paper prescription. ePrescribing a Schedule II opioid after a first-ever telehealth encounter with no prior relationship and no in-person examination is, in most circumstances, not lawful — full stop.